A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and ...

For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...